Trade Basilea Pharma AG - BSLN CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.5
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investmentCHF 1,000.00Overnight funding adjustmentCharges from full value of position-0.010846 %(-CHF 2.17)Trade size with leverage ~ CHF 20,000.00Money from leverage ~ $CHF 19,000.00Go to platform: -0.01085%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investmentCHF 1,000.00Overnight funding adjustmentCharges from full value of position-0.011376 %(-CHF 2.28)Trade size with leverage ~ CHF 20,000.00Money from leverage ~ $CHF 19,000.00Go to platform: -0.01138%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: CHF
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: Switzerland
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: CHF 1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.010846 %
  (-CHF 2.17)

• Margin. Your investment: CHF 1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.011376 %
  (-CHF 2.28)

Key Stats

• Prev. Close: 65.7
• Open: 64.9
• 1-Year Change: 29.03%
• Day's Range: 63.7 - 66.3

Trade Basilea Pharma AG - BSLN

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. It launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Basilea Pharmaceutica AG revenues increased 16% to SF148.1M. Net loss decreased 54% to SF6.8M. Revenues reflect Japan segment increase of 41% to SF56.5M, Republic of Ireland segment increase of 9% to SF62.1M. Lower net loss reflects Research & development expenses, net - B decrease of 4% to SF91.6M (expense), Stock-based Compensation in SGA decrease of 6% to SF1.7M (expense).